Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UroGen Pharma Ltd.URGN · Entity 4466 | Chief Medical Officer | September 07, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UroGen Pharma Ltd.
Report date September 07, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 59,882 |
Ending reported balance
After 2026-09-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-07 · Exercise / conversion · Acquired 1,667 · Balance 60,753 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Row 2 · 2026-09-08 · Sale · Disposed 871 · Balance 59,882 F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-07 · Exercise / conversion · Disposed 1,667 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3: The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3: The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 9, 2026 18:37 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 871 | $42.92 | $37,383.32 |
DisclosureSEC source: 0001437749-26-029965 · rdgdoc.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,882 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| September 07, 2026 Filed Sep 9, 2026 18:37 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-029965 · rdgdoc.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. F3 · derivative.expiration_date: The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. Read SEC document |
| September 07, 2026 Filed Sep 9, 2026 18:37 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-029965 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 21:03 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Saleordinary shares | 60,677 | $47.05 | $2,854,852.85 |
DisclosureSEC source: 0001437749-26-028840 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,086 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.30 to $49.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 09, 2026 Filed Jul 10, 2026 18:17 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 10,000 | $40.00 | $400,000.00 |
DisclosureSEC source: 0001437749-26-023290 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,763 F1 · kind: Transaction made pursuant to a duly adopted trading plan under Rule 10b5-1(c). The adoption date of the referenced Rule 10b5-1(c) plan is August 15, 2025. This transaction represents the final sale under such trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 and $40.02. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 14:22 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 10,000 | $35.01 | $350,100.00 |
DisclosureSEC source: 0001437749-26-021523 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,763 F1 · kind: Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). Adoption date of referenced 10b5-1(c) plan is: 08-15-2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 and $35.08. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 17:59 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-019964 · rdgdoc.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024. F3 · derivative.expiration_date: The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 17:59 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 5,222 | $27.30 | $142,560.60 |
DisclosureSEC source: 0001437749-26-019964 · rdgdoc.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,763 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 17:59 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-019964 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| May 08, 2026 Filed May 11, 2026 19:54 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 10,000 | $30.00 | $300,000.00 |
DisclosureSEC source: 0001437749-26-016104 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,985 F1 · kind: Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). Adoption date of referenced 10b5-1(c) plan is: 08-15-2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 and $30.05. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 00:37 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 3,686 | $19.69 | $72,577.34 |
DisclosureSEC source: 0001437749-26-003040 · rdgdoc.xml · nonDerivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,985 F1 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 00:37 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,843 | $19.69 | $36,288.67 |
DisclosureSEC source: 0001437749-26-003040 · rdgdoc.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,671 F1 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 00:37 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,844 | $19.69 | $36,308.36 |
DisclosureSEC source: 0001437749-26-003040 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,514 F1 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 22:18 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-002843 · rdgdoc.xml · derivative · entry 7 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029. F5 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 22:18 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 3,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-002843 · rdgdoc.xml · derivative · entry 6 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024. F3 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 22:18 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 6,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-002843 · rdgdoc.xml · derivative · entry 5 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,334 Underlying: Ordinary Shares · 6,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2025 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2026. F2 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2025 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2026. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 22:18 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-002843 · rdgdoc.xml · derivative · entry 4 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,334 Underlying: Ordinary Shares · 3,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2024 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025. F4 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2024 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 22:18 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 3,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-002843 · rdgdoc.xml · nonDerivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 22:18 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 6,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-002843 · rdgdoc.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 22:18 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 3,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-26-002843 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,692 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| November 19, 2025 Filed Nov 20, 2025 18:42 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 10,000 | $25.00 | $250,000.00 |
DisclosureSEC source: 0001437749-25-035821 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,025 F1 · kind: Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). Adoption date of referenced 10b5-1(c) plan is: 08-15-2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 and $25.02. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 22:37 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 871 | $19.11 | $16,644.81 |
DisclosureSEC source: 0001437749-25-028707 · rdgdoc.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,025 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| September 07, 2025 Filed Sep 9, 2025 22:37 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-028707 · rdgdoc.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,667 Underlying: Ordinary Shares · 1,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. F3 · derivative.expiration_date: The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. Read SEC document |
| September 07, 2025 Filed Sep 9, 2025 22:37 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-028707 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 13:58 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 10,000 | $17.69 | $176,900.00 |
DisclosureSEC source: 0001437749-25-026377 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,229 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.63 and $17.76. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:02 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 5,149 | $19.14 | $98,551.86 |
DisclosureSEC source: 0001437749-25-023961 · rdgdoc.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,229 F3 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of performance stock units. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 20:02 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-023961 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the settlement of performance stock units granted on January 31, 2024 that vested upon the achievement of a corporate milestone event. F2 · price: Each performance stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| June 09, 2025 Filed Jun 11, 2025 13:14 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 5,162 | $7.37 | $38,043.94 |
DisclosureSEC source: 0001437749-25-020045 · rdgdoc.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,378 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| June 08, 2025 Filed Jun 11, 2025 13:14 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-020045 · rdgdoc.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024. F3 · derivative.expiration_date: The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024. Read SEC document |
| June 08, 2025 Filed Jun 11, 2025 13:14 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-020045 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002688 · rdgdoc.xml · derivative · entry 10 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 20,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F6 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2026, January 31, 2027 and January 31, 2028. F6 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2026, January 31, 2027 and January 31, 2028. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002688 · rdgdoc.xml · derivative · entry 9 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,667 Underlying: Ordinary Shares · 3,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2024 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025. F5 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2024 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002688 · rdgdoc.xml · derivative · entry 8 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,334 Underlying: Ordinary Shares · 3,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024. F4 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 1,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002688 · rdgdoc.xml · derivative · entry 7 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023. F3 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2022 representing 4,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,896 | $11.14 | $21,121.44 |
DisclosureSEC source: 0001437749-25-002688 · rdgdoc.xml · nonDerivative · entry 6 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,540 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 3,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-002688 · rdgdoc.xml · nonDerivative · entry 5 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,896 | $11.14 | $21,121.44 |
DisclosureSEC source: 0001437749-25-002688 · rdgdoc.xml · nonDerivative · entry 4 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,103 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 3,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-002688 · rdgdoc.xml · nonDerivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 759 | $11.14 | $8,455.26 |
DisclosureSEC source: 0001437749-25-002688 · rdgdoc.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,666 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 16:53 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-002688 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| September 09, 2024 Filed Sep 12, 2024 17:54 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 1,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-029040 · rdgdoc.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,334 Underlying: Ordinary Shares · 1,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. F3 · derivative.expiration_date: The reporting person was granted RSUs on September 7, 2023 representing 5,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. Read SEC document |
| September 09, 2024 Filed Sep 12, 2024 17:54 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 859 | $13.08 | $11,235.72 |
DisclosureSEC source: 0001437749-24-029040 · rdgdoc.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,091 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| September 09, 2024 Filed Sep 12, 2024 17:54 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 1,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-029040 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 17:15 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-019900 · rdgdoc.xml · derivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024. F3 · derivative.expiration_date: The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 17:15 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 5,153 | $13.08 | $67,401.24 |
DisclosureSEC source: 0001437749-24-019900 · rdgdoc.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,284 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 17:15 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-24-019900 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:38 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 12,000 | $14.05 | $168,600.00 |
DisclosureSEC source: 0001437749-24-008707 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,437 F1 · shares: A portion of the cash receipts will be used for federal income tax purposes Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 02:15 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,894 | $15.78 | $29,887.32 |
DisclosureSEC source: 0001437749-24-003153 · rdgdoc.xml · nonDerivative · entry 3 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,437 F1 · date: This amendment corrects and restates the date of sale reported in the original Form 4 filed on February 2, 2024. F2 · price: This amendment corrects and restates the sales price reported in the original Form 4 filed on February 2, 2024. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 02:15 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 758 | $15.78 | $11,961.24 |
DisclosureSEC source: 0001437749-24-003153 · rdgdoc.xml · nonDerivative · entry 2 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,998 F1 · date: This amendment corrects and restates the date of sale reported in the original Form 4 filed on February 2, 2024. F2 · price: This amendment corrects and restates the sales price reported in the original Form 4 filed on February 2, 2024. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 02:15 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,137 | $15.78 | $17,941.86 |
DisclosureSEC source: 0001437749-24-003153 · rdgdoc.xml · nonDerivative · entry 1 Schoenberg Mark · CIK 0001763581 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,423 F1 · date: This amendment corrects and restates the date of sale reported in the original Form 4 filed on February 2, 2024. F2 · price: This amendment corrects and restates the sales price reported in the original Form 4 filed on February 2, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.